ArticleAmerican journal of translational research2020

MARK2 enhances cisplatin resistance via PI3K/AKT/NF-κB signaling pathway in osteosarcoma cells.

Xianfu Wei et al.PubMed ↗Full text ↗

No numbers read from the abstract.